TABLE 1.
Main features of the 64 study patients, including 31 with classical idiopathic inflammatory myositis (c‐IIM) and 33 with amyopathic idiopathic inflammatory myositis (a‐IIM)
| Overall n = 64 | c‐IIM n = 31 | a‐IIM n = 33 | p‐value | |
|---|---|---|---|---|
| Male, n (%) | 35 (55) | 14 (45) | 21 (64) | .22 |
| Recipient age (years), med [IQR] | 53 [46–59] | 55 [46–59] | 52 [46–56] | .71 |
| Body mass index, kg/m2 | 26 [23–29] | 25 [24–28] | 27 [23–29] | .29 |
| Caucasian, n (%) | 49 (77) | 22 (71) | 27 (82) | .10 |
| Smoking history (pack‐years), med [IQR], n = 44 | 12 [0–20] | 15 [10–20] | 6 [0–21] | .22 |
| CMV: donor positive / recipient negative, n (%), n = 56 | 4 (7%) | 0 | 4 (13) | .11 |
| Blood group, A/O/B/AB, %, n = 55 | 40/34/17/9 | 38/46/12/4 | 38/34/17/11 | .92 |
| Lung transplantation procedure: double/single, n (%) | 56 (87)/8 (13) | 27 (87)/4 (13) | 29 (87)/4 (13) | .99 |
| High‐priority transplant allocation program, n (%) | 21 (33) | 10 (32) | 11 (33) | .99 |
| Pulmonary hypertension, n (%), n = 39 | 29 (74) | 17 (89) | 12 (60) | .07 |
| Severe pulmonary hypertension, n (%), n = 39 | 13 (33) | 7 (37) | 6 (30) | .91 |
| Preoperative extracorporeal membrane oxygenation, n (%) | 13 (21) | 4 (13) | 9 (27) | .21 |
| Intraoperative extracorporeal membrane oxygenation, n (%) | 32 (50) | 12 (39) | 20 (61) | .13 |
| Postoperative extracorporeal membrane oxygenation, n (%) | 25 (39) | 12 (39) | 13 (39) | .99 |
| Induction, n (%) | 28 (44) | 14 (45) | 14 (42) | .99 |
| Dialysis during intensive care unit stay, n (%) | 12 (19) | 7 (23) | 5 (15) | .53 |
| Primary graft dysfunction Grade 3 at 72 h, n (%) | 17 (29) | 10 (36) | 7 (23) | .46 |
| Ventilation time during intensive care unit stay (days), med [IQR] | 6 [1–22] | 4 [1–16] | 11 [3–22] | .13 |
| Hemothorax, n (%), n = 63 | 14 (22) | 7 (23) | 7 (22) | .99 |
| Pneumonia requiring hospitalization during the first posttransplantation year, n (%), n = 50 | 25 (50) | 12 (46) | 13 (54) | .78 |
| Acute cellular rejection ≥grade 2 during the first posttransplantation year, n (%), n = 53 | 5 (9) | 2 (7) | 3 (12) | .63 |
| Preformed donor‐specific antibody, n (%) | 12 (19) | 7 (23) | 5 (16) | .75 |
| Antibody‐mediated rejection during the first posttransplantation year, n (%), n = 59 | 6 (10) | 1 (3) | 5 (17) | .11 |
| Chronic lung allograft dysfunction at last follow‐up, n (%), n = 57 | 13 (23) | 8 (29) | 5 (17) | .52 |
| Bronchiolitis obliterans syndrome | 10 (77) | 6 (76) | 4 (80) | |
| Restrictive allograft syndrome | 2 (15) | 1 (12) | 0 | |
| Mixed | 1 (8) | 1 (12) | 1 (20) | |
| Cancer after transplantation, n (%) | 3 (5) | 3 (10) | 0 | .11 |
| Deaths, n (%) | 19 (30) | 16 (52) | 3 (9) | <.01 |
| In‐hospital mortality, n (%) | 11 (17) | 8 (26) | 3 (9) | .10 |
| Causes of death, n (%) | .49 | |||
| Septic shock | 5 (26) | 3 (19) | 2 (67) | |
| Primary graft dysfunction | 4 (21) | 4 (25) | 0 | |
| Pneumonia | 4 (21) | 4 (25) | 0 | |
| Other | 6 (32) | 5 (31) | 1 (33) |
Abbreviations: a‐IIM, amyopathic idiopathic inflammatory myositis; c‐IIM, classical idiopathic inflammatory myositis; CMV, cytomegalovirus.